(Q36627254)

15 August 2017

1 reference

title

Recent developments in colorectal cancer treatment by monoclonal antibodies (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

Dominique Arsene

1

1 reference

15 August 2017

Marie-Pierre Galais

series ordinal

2

1 reference

15 August 2017

Karine Bouhier-Leporrier

series ordinal

3

1 reference

15 August 2017

Jean-Marie Reimund

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Biological Therapy

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

11

1 reference

15 August 2017

1175-1192

1 reference

15 August 2017

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Adjuvant therapy for colon cancer 2005: new options in the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Metastatic colorectal cancer: first- and second-line treatment in 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Monoclonal antibodies in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

The epidermal growth factor receptor as a target for colorectal cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

The biology of the 17-1A antigen (Ep-CAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Radioimmunotherapy of prostate cancer: does tumor size matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Bevacizumab plus fluorouracil: the value of being part of a developing story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

New treatment options for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Responsiveness to cetuximab without mutations in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Molecular and pathologic aspects of endometrial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Radiation therapy and tamoxifen: concurrent or sequential? That is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

Pharmacogenomics in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1175

10.1517/14712598.6.11.1175

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference